1,024 results match your criteria melphalan 100


Second stem cell transplantation for relapsed refractory light chain (AL) amyloidosis.

Transplant Cell Ther 2021 Apr 8. Epub 2021 Apr 8.

Division of Hematology, Mayo Clinic, Rochester, MN, USA. Electronic address:

Background: Autologous stem cell transplantation (ASCT) is an effective treatment modality in light chain (AL) amyloidosis but can be offered only to a subset of patients. The feasibility, benefit and risks of second ASCT (ASCT2) were rarely reported .

Objective: To assess the utility of ASCT2 in AL amyloidosis and to identify the target population with the greatest benefit . Read More

View Article and Full-Text PDF

Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma.

Adv Ther 2021 Mar 26. Epub 2021 Mar 26.

Department of Pharmacy, The Second Xiangya Hospital of Central South University, No.139 Renmin Middle Road, Changsha, 410011, Hunan, China.

Introduction: The ALCYONE trial found that daratumumab in combination with bortezomib, melphalan, and prednisone (D-VMP) can significantly improve progression-free survival (PFS) and overall survival (OS) for patients with transplant-ineligible, newly diagnosed multiple myeloma (MM) in China. In the present study, we evaluated the cost-effectiveness of D-VMP versus VMP for patients with newly diagnosed MM in China.

Methods: A Markov model was used to estimate the cost-effectiveness of frontline D-VMP versus VMP for MM. Read More

View Article and Full-Text PDF

MUK OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia.

BMJ Open 2021 Mar 24;11(3):e046225. Epub 2021 Mar 24.

Centre for Myeloma Research, Institute of Cancer Research, London, UK

Introduction: Multiple myeloma (MM) is a plasma cell tumour with over 5800 new cases each year in the UK. The introduction of biological therapies has improved outcomes for the majority of patients with MM, but in approximately 20% of patients the tumour is characterised by genetic changes which confer a significantly poorer prognosis, generally termed high-risk (HR) MM. It is important to diagnose these genetic changes early and identify more effective first-line treatment options for these patients. Read More

View Article and Full-Text PDF

Sustained remission of multi-line relapsed extranodal NK/T-cell lymphoma, nasal type, following sintilimab and chidamide: A case report.

Medicine (Baltimore) 2021 Mar;100(10):e24824

Department of Hematology.

Introduction: There is currently no optimal treatment modality for refractory or relapsed Extranodal NK/T-cell lymphoma, nasal type (ENKTL). In recent years, programmed cell death protein 1 (PD-1)/programmed cell - ligand 1 pathway blockade and histone deacetylase inhibitors have emerged as promising strategies for refractory or relapsed ENKTL. Accumulating evidence has shown that therapeutic effects of anti-PD-1 antibody could be enhanced by histone deacetylase inhibitors. Read More

View Article and Full-Text PDF

Prospective analysis of BKV hemorrhagic cystitis in children and adolescents undergoing hematopoietic cell transplantation.

Ann Hematol 2021 May 4;100(5):1283-1293. Epub 2021 Mar 4.

Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland.

BK virus is one of the most common causes of hemorrhagic cystitis (HC) in children undergoing hematopoietic cell transplantation (HCT). Viruses can be found in urine and serum samples of immunocompromised patients. Malignant diseases, age, cell source, day of granulocyte reconstitution, conditioning regimen, or use of total body irradiation may play an important role in BKV epidemiology, development of hemorrhagic cystitis course, and outcome. Read More

View Article and Full-Text PDF

[Cooccurrence of classic Hodgkin lymphoma and multiple myeloma].

Rinsho Ketsueki 2021 ;62(1):14-19

Department of Hematology/Oncology, Research Hospital, the Institute of Medical Science, the University of Tokyo.

Although classic Hodgkin's lymphoma (CHL) sometimes develops after treatment for multiple myeloma (MM), simultaneous diagnosis of both malignancies is extremely rare without previous treatment history. Here we describe a case of a 54-year-old female who complained of left cervical lymphadenopathy. Biopsy specimen from the left cervical lymph node revealed mixed-cellularity CHL. Read More

View Article and Full-Text PDF
February 2021

Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency Diseases.

J Clin Immunol 2021 Feb 1. Epub 2021 Feb 1.

Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.

Purpose: The purpose of our study was to compare the safety and efficacy of hematopoietic cell transplantation (HCT) using fludarabine (Flu)-based reduced intensity conditioning (RIC) with busulfan (BU) or melphalan (Mel) for primary immunodeficiency diseases (PID).

Methods: We retrospectively analyzed transplant outcome, including engraftment, chimerism, immune reconstitution, and complications in 15 patients with severe combined immunodeficiency (SCID) and 27 patients with non-SCID PID. The patients underwent Flu-based RIC-HCT with BU (FluBU: 7 SCID, 16 non-SCID) or Mel (FluMel: 8 SCID, 11 non-SCID). Read More

View Article and Full-Text PDF
February 2021

Gastrointestinal toxicity of high-dose melphalan in autologous hematopoietic stem cell transplantation: identification of risk factors and a benchmark for experimental therapies.

Ann Hematol 2021 Jan 3. Epub 2021 Jan 3.

Department of Medicine, Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, NY, USA.

Gastrointestinal side effects are the dose-limiting toxicity of high-dose melphalan (HDM) in autologous hematopoietic stem-cell transplantation, but there are limited contemporary data on the incidence and severity of gastrointestinal toxicity associated with this regimen. We retrospectively studied 100 consecutive patients who received HDM alone or in combination with other conditioning agents. Patients had a median age of 56 (range 20-73); underlying diseases were myeloma (42%), lymphoma (42%), or amyloidosis (16%) and melphalan dosages were 200 (40%), 140 (59%), or 100 mg/m (1%). Read More

View Article and Full-Text PDF
January 2021

[Autologous haematopoietic stem cell transplantation in patients with multiple myeloma complicated by dialysis-dependent renal failure].

Ter Arkh 2020 Sep 1;92(7):70-76. Epub 2020 Sep 1.

National Research Center for Hematology.

Aim: To assess the safety and efficacy of autologous haematopoietic stem cell transplantation (auto-HSCT) in multiple myeloma (MM) patients with dialysis-dependent renal failure.

Materials And Methods: During a period from May 2010 to December 2016 fourteen MM patients with dialysis-dependent renal failure aged 48 to 65 years underwent auto-HSCT. After the induction therapy complete response, very good partial response, partial response were documented in 64, 29, 7% of patients, respectively. Read More

View Article and Full-Text PDF
September 2020

Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents.

Bone Marrow Transplant 2020 Dec 4. Epub 2020 Dec 4.

Division of Hematology, Mayo Clinic, Rochester, MN, USA.

Autologous stem cell transplantation (ASCT) has been used for treating multiple myeloma (MM) for over three decades and is generally reserved for patients younger than 65. Herein we report on outcomes of outpatient ASCT in a cohort of patients with MM aged ≥75 years. Between October 2005 and August 2020, 50 patients aged ≥75 years, received an ASCT at Mayo Clinic, Rochester. Read More

View Article and Full-Text PDF
December 2020

Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas.

Ann Hematol 2021 Jan 17;100(1):189-196. Epub 2020 Nov 17.

Department of Hematology and Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.

Given the unsatisfactory survival in patients who received high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) for peripheral T-cell lymphomas (PTCLs), we conducted a prospective trial of busulfan (Bu), etoposide (E), cytarabine (A), and melphalan (M) (BuEAM), including IV Bu instead of carmustine (BCNU) as in standard BEAM, as a high-dose regimen in such patients. This study evaluated the efficacy and toxicity of BuEAM as a high-dose regimen for ASCT in patients with T-cell lymphomas. The high-dose chemotherapy at seven centers in Korea included Bu (3. Read More

View Article and Full-Text PDF
January 2021

Mexican Concensus of Multiple Myeloma.

Authors:
José A de la Peña-Celaya Jocelyn Aguilar-Luevano Luisa Ma Alcivar-Cedeño José L Álvarez-Vera Irene Anaya-Cuellar Erika Añorve-Hernández Luara L Arana-Luna Luis Arteaga-Ortíz Pamela E Báez-Islas Luisa I Banda-García Ramón A Bates-Martín Dafne Itzel Campa-Monroy Mariela Cardiel-Silva Ángel de Jesús Castillo-Salas Xóchitl Cota-Rangel Guillermo Díaz-Vargas M Eugenia Espitia-Ríos Patricia Estrada-Domínguez Denisse Fermín-Caminero Alinka García-Camacho Carolina García-Castillo Katheryn B Garzón-Velásquez Carlos Gil-Rondero Lidia V Guerra-Alarcón Ana K Hernández-Colín Eleazar Hernández-Ruiz Areli E Hernández-Alcántara Silvia A Hernández-Cervantes Wilfrido Herrera-Olivares Gregorio Ignacio-Ibarra Sergio I Inclán-Alarcón Faustino Leyto-Cruz Juan P Macías-Flores Andrea Martínez-de la Vega Mario Alberto Martínez-Ramírez Jorge Martínez-Coronel Jesús Emanuel Medina-Coral Lizeth Meza-Dávalos Leire Montoya-Jiménez Alba Morales-Hernández Elizabeth Morales-López Javier de Jesús Morales-Adrián Maricruz Morales-de Azcué Aldo Mújica-Martínez Juan L Murillo-Cruz Jéssica Nájera-Martínez Iris Mabel Narváez-Sarmiento Lorena Nava-Villegas Marco A Nava-Alpide Juan J Orellana Garibay Ma Teresa Palafox-Zaldívar Orlando G Palma-Moreno Eugenia P Paredes-Lozano Ma Luisa Pedraza-Colín Juan M Pérez-Zúñiga Alejandra B Pérez-Lizardi Flavio Rojas-Castillejos Eduardo Romero-Martínez Hilda Romero-Rodelo Josué Ruiz-Contreras Azucena Saavedra-González Erick Saucedo-Montes Luis G Silva-Michel Karina Silva-Vera Óscar Teomitzi-Sánchez Fredy Tepepa-Flores Yanet Ventura-Enríquez Atenas Villela-Peña Shendel P Vilchis-González Nidia Zapata-Canto Pedro A Zárate-Rodríguez Martha Alvarado-Ibarra

Gac Med Mex 2020 ;156(Suppl 1):S1-S45

Servicio de Hematología, Centro Médico Nacional 20 de Noviembre, ISSSTE Ciudad de Mexico. México.

To identify this increasingly common pathology, known as multiple myeloma (MM), it is necessary to refer to the specific factors that characterize it; to this end, the classic criteria known as CRAB (hyperkalemia, renal failure, anemia, and lytic lesions) are available, in which renal failure is one of the most frequent complications. Recently, three indisputable biomarkers have been described for the diagnostic support for MM, which are: more than 10% of clonal plasma cells in bone marrow or, a biopsy that corroborates the presence of a plasmacytoma, light chain ratio ≥ 100 mg/dL and more than one focal lesion on magnetic resonance imaging. A differential diagnosis for plasma cell leukemia, solitary bone plasmacytoma, and extramedullary plasmacytoma should always be considered. Read More

View Article and Full-Text PDF
January 2020

A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trial.

Br J Haematol 2021 01 21;192(1):119-128. Epub 2020 Oct 21.

Division of Hematology, Ospedali Civili di Brescia, Brescia, Italy.

A few prospective trials in HIV-positive patients with Burkitt lymphoma (BL) or high-grade B-cell lymphoma (HGBL) have been reported. Investigated therapies have shown good efficacy but relevant safety problems, with high rates of interruptions, severe mucositis, septic complications, and fungal infections. Here, we report the results of a multicentre phase II trial addressing a new dose-dense, short-term therapy aimed at maintaining efficacy and improving tolerability. Read More

View Article and Full-Text PDF
January 2021

EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma.

Oncologist 2020 12 16;25(12):1067-1074. Epub 2020 Oct 16.

European Medicines Agency, Amsterdam, The Netherlands.

The use of daratumumab in combination with established regimens for the treatment of newly diagnosed multiple myeloma has recently been authorized by the European Medicines Agency based on results from three separate phase III randomized, active controlled, open-label studies that have confirmed enhanced efficacy and tolerability in both transplant-ineligible (MMY3008 and MMY3007) and transplant-eligible (MMY3006) patients, without compromising transplant ability. Trial MMY3008 showed an improvement in progression-free survival (PFS) when daratumumab was added to lenalidomide and dexamethasone compared with lenalidomide and dexamethasone; the median PFS had not been reached in the daratumumab arm and was 31.9 months in the control arm (hazard ratio [HR], 0. Read More

View Article and Full-Text PDF
December 2020

Irradiation-free RIC HSCT has a tolerable safety profile and is effective therapy for pediatric bone marrow failure syndromes.

Pediatr Transplant 2021 Mar 6;25(2):e13855. Epub 2020 Oct 6.

UCSD School of Medicine, La Jolla, CA, USA.

For patients with bone marrow failure syndromes (BMFS) who may tolerate gradual donor engraftment and achieve adequate disease control with stable mixed chimerism, RIC regimens may be preferable to myeloablative regimens. We performed a retrospective analysis of outcomes for patients who underwent HSCT at our institution between 2009 and 2017 for BMFS using an irradiation-free RIC regimen. Fourteen pediatric patients with BMFS received fludarabine (30 mg/m IV daily × 3), thiotepa (5 mg/kg IV every 12 hours × 2), and melphalan (70 mg/m IV daily × 2) prior to HSCT. Read More

View Article and Full-Text PDF

Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma.

Transplant Cell Ther 2021 Jan 25;27(1):57.e1-57.e8. Epub 2020 Sep 25.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington. Electronic address:

Autologous hematopoietic cell transplantation (AHCT) is a standard of care for several subtypes of high-risk lymphoma, but durable remissions are not achieved in the majority of patients. Intensified conditioning using CD45-targeted antibody-radionuclide conjugate (ARC) preceding AHCT may improve outcomes in lymphoma by permitting the delivery of curative doses of radiation to disease sites while minimizing toxicity. We performed sequential phase I trials of escalating doses of yttrium-90 (Y)-labeled anti-CD45 antibody with or without BEAM (carmustine, etoposide, cytarabine, melphalan) chemotherapy followed by AHCT in adults with relapsed/refractory or high-risk B cell non-Hodgkin lymphoma (NHL), T cell NHL (T-NHL), or Hodgkin lymphoma (HL). Read More

View Article and Full-Text PDF
January 2021

Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma.

Cancer 2020 Dec 23;126(23):5077-5087. Epub 2020 Sep 23.

Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin.

Background: Upfront autologous hematopoietic stem cell transplantation (AHCT) remains an important therapy in the management of patients with multiple myeloma (MM), a disease of older adults.

Methods: The authors investigated the outcomes of AHCT in patients with MM who were aged ≥70 years. The Center for International Blood and Marrow Transplant Research (CIBMTR) database registered 15,999 patients with MM in the United States within 12 months of diagnosis during 2013 through 2017; a total of 2092 patients were aged ≥70 years. Read More

View Article and Full-Text PDF
December 2020

Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma.

Biol Blood Marrow Transplant 2020 12 11;26(12):2229-2236. Epub 2020 Sep 11.

Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Blood and Marrow Transplant & Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, Wisconsin; Center for International Blood and Marrow Transplant Research, Milwaukee Campus, Milwaukee, Wisconsin. Electronic address:

High-dose melphalan (Mel) conditioning before autologous hematopoietic cell transplantation (autoHCT) is standard of care for patients with transplantation-eligible multiple myeloma. The traditional lyophilized Mel formulation has inadequate solubility and stability after reconstitution, leading to the use of propylene glycol (PG) as a solubilizing agent. A newer PG-free Mel preparation (Evomela) uses beta cyclodextrin captisol as a solubilizing agent and was approved by the United States Food and Drug Administration as a conditioning agent based on a single-phase IIb study showing bioequivalence. Read More

View Article and Full-Text PDF
December 2020

BEAM-Campath Allogeneic Stem Cell Transplant for Patients with Relapsed/Refractory Lymphoma: High Incidence of Long-Term Mixed Donor-Recipient Chimerism and the Response to Donor Lymphocyte Infusions.

Biol Blood Marrow Transplant 2020 12 3;26(12):2271-2278. Epub 2020 Sep 3.

University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom.

BiCNU (carmustine), etoposide, Ara-C, melphalan (BEAM) and Campath conditioning was developed to reduce the high transplant-related mortality in patients with lymphoma while delivering intensive antilymphoma immunotherapy, as well as to some extent a platform for allogeneic stem cell engraftment. Significant numbers of patients appeared to have persistent recipient-derived hematopoiesis, and therefore we retrospectively analyzed patients with lymphoma undergoing BEAM-Campath conditioned allogeneic stem cell transplantation at our center (2003 to 2017) to characterize the patterns of chimerism and patient outcomes. Chimerism was analyzed with short tandem repeat PCR. Read More

View Article and Full-Text PDF
December 2020

Timing of Alemtuzumab With Respect to Day of Bone Marrow Infusion and its Effects Upon Engraftment and Graft-Versus-Host Disease in Patients With Sickle Cell Disease: A Single-Institutional Study.

J Pediatr Hematol Oncol 2020 11;42(8):e718-e722

Division of Pediatric Hematology/Oncology and Stem Cell Transplantation, Department of Pediatrics, Cohen Children's Medical Center of New York, New Hyde Park, NY.

The possible impact of "late" alemtuzumab (administered on days -10 to -8) versus "early" alemtuzumab (-19 to -17) with respect to engraftment and acute/chronic graft-versus-host disease (GvHD) in a group of 25 pediatric patients with sickle cell disease undergoing bone marrow transplantation following conditioning with alemtuzumab, fludarabine, and melphalan is reported. The first 9 patients received "late" alemtuzumab followed by bone marrow transplantation from HLA-matched sibling donors. The next 16 patients undergoing matched sibling transplants received "early" alemtuzumab. Read More

View Article and Full-Text PDF
November 2020

Intra-arterial Chemotherapy as Primary Treatment for Cavitary Retinoblastoma: Excellent Response in Eight Tumors.

Ophthalmol Retina 2020 Aug 24. Epub 2020 Aug 24.

Vanderbilt University School of Medicine, Nashville, Tennessee; Division of Ocular Oncology and Pathology, Department of Ophthalmology and Visual Sciences, Vanderbilt University Medical Center, Nashville, Tennessee; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee; Program in Cancer Biology, Vanderbilt University, Nashville, Tennessee. Electronic address:

Purpose: The "cavitary" form of retinoblastoma has historically demonstrated minimal treatment response with intravenous chemoreduction, showing less robust regression and less reduction in tumor size. Intra-arterial chemotherapy (IAC) has been reported to more effectively treat retinoblastoma, allowing many previously unsalvageable eyes to now be saved. The purpose was to report treatment response of cavitary retinoblastoma tumors to IAC. Read More

View Article and Full-Text PDF

Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease.

Blood Adv 2020 08;4(16):3894-3899

Department of Pediatrics, Washington University School of Medicine, St. Louis, MO.

We report results of a phase 1 multicenter stem cell transplantation (SCT) trial from HLA-matched (n = 7) or one-antigen-mismatched (n = 7) unrelated donors (URD) using bone marrow or cord blood as stem cell source, following reduced-intensity conditioning (RIC) in severe sickle cell disease (SCD). Conditioning included distal alemtuzumab, fludarabine, and melphalan (matched donors), with thiotepa (mismatched donors). Abatacept, a selective inhibitor of T cell costimulation, was added to tacrolimus and methotrexate as graft-versus-host disease (GVHD) prophylaxis to offset GVHD risks, and was administered for longer duration in bone marrow recipients than in cord blood recipients because of increased incidence of chronic GVHD with bone marrow. Read More

View Article and Full-Text PDF

Phase II study of reduced-dose craniospinal irradiation and combination chemotherapy for children with newly diagnosed medulloblastoma: A report from the Japanese Pediatric Brain Tumor Consortium.

Pediatr Blood Cancer 2020 11 25;67(11):e28572. Epub 2020 Jul 25.

Department of Pediatric Hematology/Oncology, Osaka City General Hospital, Osaka, Japan.

Background: Standard doses of craniospinal irradiation (CSI) are 23.4 Gy for patients with average-risk and 36 Gy for those with high-risk medulloblastoma (MB). We investigated whether intensified chemotherapy including intrathecal chemotherapy with simultaneous irradiation is able to reduce CSI dose to 18 Gy. Read More

View Article and Full-Text PDF
November 2020

COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers.

medRxiv 2020 Jun 11. Epub 2020 Jun 11.

Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Importance: New York City is a global epicenter for the SARS-CoV-2 outbreak with a significant number of individuals infected by the virus. Patients with multiple myeloma have a compromised immune system, due to both the disease and anti-myeloma therapies, and may therefore be particularly susceptible to coronavirus disease 2019 (COVID-19); however, there is limited information to guide clinical management.

Objective: To assess risk factors and outcomes of COVID-19 in patients with multiple myeloma. Read More

View Article and Full-Text PDF

Impact of melphalan dose during reduced-intensity conditioning on engraftment of cord blood transplantation for chronic Epstein-Barr virus-associated T or NK cell lymphoproliferative diseases.

Pediatr Blood Cancer 2020 09 21;67(9):e28536. Epub 2020 Jun 21.

Department of Hematology/Oncology, Osaka Women's and Children's Hospital, Osaka, Japan.

The rejection rate in cord blood transplants for chronic Epstein-Bar virus-associated T or natural killer cell lymphoproliferative diseases using our standard reduced-intensity conditioning "LPAM140 regimen," which includes fludarabine, melphalan (LPAM), etoposide, and antithymocyte globulin, has been high. To ensure better engraftment, we increased the LPAM dose to 210 mg/m ("LPAM210 regimen"). Patient data (n = 22; LPAM140, n = 7; LPAM210, n = 15) were analyzed retrospectively. Read More

View Article and Full-Text PDF
September 2020

Cord blood transplants supported by unrelated donor CD34 progenitor cells.

Bone Marrow Transplant 2020 12 9;55(12):2298-2307. Epub 2020 Jun 9.

Department of Medicine, Division of Hematology/Oncology, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY, USA.

Alternative donor transplantation with the haplo-cord platform allows the use of a lower-dose single umbilical cord blood unit (CBU) by co-infusion of third-party CD34-selected cells from a haploidentical relative, which provides early transient engraftment while awaiting durable CBU engraftment. In our experience, ~15% of patients lack a suitable haploidentical donor. Here we report 26 patients who underwent haplo-cord transplant using CD34-selected partially matched unrelated donor grafts. Read More

View Article and Full-Text PDF
December 2020

Treatment with intravenous busulfan, melphalan, and etoposide followed by autologous stem cell transplantation in patients with non-Hodgkin's lymphoma: a multicenter study from the consortium for improving survival of lymphoma.

Transpl Int 2020 Oct 23;33(10):1211-1219. Epub 2020 Jul 23.

Division of Hematology & Oncology, Department of Internal Medicine, Soonchunhyang University College of Medicine, Soonchunhyang University Hospital, Seoul, Korea.

Several high-dose therapy (HDT) conditioning regimens have been used to treat non-Hodgkin's lymphoma (NHL), such as bis-chloroethylnitrosourea (BCNU)/etoposide/cytosine arabinoside/melphalan (BEAM), BCNU/etoposide/cytosine arabinoside/cyclophosphamide (BEAC), and cyclophosphamide/BCNU/etoposide (CBV). BCNU is an active drug in HDT of NHL, but the supply is limited in some countries, including Korea. Busulfan has been used in allogeneic and autologous stem cell transplantation (ASCT). Read More

View Article and Full-Text PDF
October 2020

Anti-inflammatory and cytotoxic evaluation of extracts from the flowering stage of Celosia argentea.

BMC Complement Med Ther 2020 May 24;20(1):152. Epub 2020 May 24.

Medicinal Plants and Economic Development (MPED) Research Centre, Department of Botany, University of Fort Hare, Alice, 5700, South Africa.

Background: This study was aimed at investigating the possible anti-inflammatory and cytotoxic effects of extracts from the flowering stage of C. argentea. This growth stage was chosen because of its high polyphenolic content and high antioxidant capacity. Read More

View Article and Full-Text PDF